Understanding and Inhibiting the P450 CYP24 enzyme, a target for cancer chemotherapeutics.

了解和抑制 P450 CYP24 酶（癌症化疗的靶点）。

• 批准号: DP0881116
• 负责人: Prof James De Voss
• 金额: $ 16.99万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0881116
• 关键词: Understanding; Inhibiting; P450; CYP24; enzyme

This project falls within the National Research Priority of Promoting and Maintaining Good Health in the category of ageing well and productively. CYP24 inhibition provides a particular target for breast and prostate cancer which are the second leading cause of death in women and men, respectively. The proposed research will result in the production of CYP24 inhibitors that will be assessed in vivo at the Hanson Institute in Adelaide as potential anti-cancer drugs. Finally, there is a significant benefit in technology transfer to Australia from our collaborators in the USA in the field of computer aided inhibitor design.

该项目属于促进和保持良好健康的国家研究优先事项，属于健康和富有成效地老龄化范畴。抑制CYP24为乳腺癌和前列腺癌提供了一个特殊的靶点，这两种癌症分别是女性和男性的第二大死亡原因。拟议的研究将导致CYP24抑制剂的生产，这些抑制剂将在阿德莱德的汉森研究所作为潜在的抗癌药物进行体内评估。最后，在计算机辅助抑制剂设计领域，我们在美国的合作者向澳大利亚转移技术有一个显著的好处。